Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 841-851

  Barcia Macay, Maritza ^a   Seral, Cristina ^a,b   Mingeot Leclercq, Marie Paule ^a   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; GARENOXACIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; NAFCILLIN; ORITAVANCIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; OXYTETRACYCLINE; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELITHROMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CULTURE MEDIUM; DOSE RESPONSE; DRUG CHOICE; DRUG POTENCY; HUMAN; HUMAN CELL; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CELL LINE; CULTURE MEDIA; GLYCOPEPTIDES; HUMANS; HYDROGEN-ION CONCENTRATION; LACTAMS, MACROCYCLIC; MACROLIDES; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; QUINOLONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33644656768     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.841-851.2006     Document Type: Article

References (71)

1. Alexander, E. H., and M. C. Hudson. 2001. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl. Microbiol. Biotechnol. 56:361-366.
2. Al Nawas, B., and P. M. Shah. 1998. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 41:655-658.
3. Allen, N. E., and T. I. Nicas. 2003. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26:511-532.
4. Amsden, G. W., and J. J. Schentag. 1995. Tables of antimicrobial agent pharmacology, p. 492-529. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
5. Anonymous. 2005. Zyvox US full prescribing information. http://www.pfizer.com/pfizer/download/uspi_zyvox.pdf. Pharmacia & Upjohn, Division of Pfizer Inc, New York, N.Y. (last updated, May 2005; last accessed, 18 July 2005).
6. Auwerx, J. 1991. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47:22-31.
7. Berrington, A. W., R. J. Koerner, J. D. Perry, H. H. Bain, and F. K. Gould. 2001. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int. J. Med. Microbiol. 291:237-239.
8. Bishayi, B., and M. Sengupta. 2003. Intracellular survival of Staphylococcus aureus due to alteration of cellular activity in arsenic and lead intoxicated mature Swiss albino mice. Toxicology 184:31-39.
9. Braun, D. K., J. K. Chien, D. S. Farlow, D. L. Phillips, M. W. Wasilewski, and M. L. Zeckel. 2001. Oritavancin (LY333328): a dose-escalation safety and pharmacokinetics study in patients. Clin. Microbiol. Infect. 7:P434.
10. Brouillette, E., G. Grondin, L. Shkreta, P. Lacasse, and B. G. Talbot. 2003. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb. Pathog. 35:159-168.
11. Carryn, S., H. Chanteux, C. Seral, M. P. Mingeot-Leclercq, F. Van Bambeke, and P. M. Tulkens. 2003. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. N. Am. 17:615-634.
12. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103.
13. Carryn, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2003. Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J. Antimicrob. Chemother. 51:1051-1052.
14. Carryn, S., S. Van de Velde, F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide. J. Infect. Dis. 189:2101-2109.
15. Craig, W. A. 2003. Basic pharmacodynamics of antibactcrials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
16. Craig, W. A., and S. C. Ebert. 1990. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 74:63-70.
17. Eckart, R. E., D. R. Hospenthal, and J. T. Fishbain. 2000. Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin. Pharmacotherapy 20:589-592.
18. Ellington, J. K., M. Harris, L. Webb, B. Smith, T. Smith, K. Tan, and M. Hudson. 2003. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J. Bone Joint Surg. Br. 85:918-921.
19. Fan, H., G. Teti, S. Ashton, K. Guyton, G. E. Tempel, P. V. Halushka, and J. A. Cook. 2003. Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B streptococci and Staphylococcus aureus. Cytokine 22:126-133.
20. Feketi, R. 2000. Vancomycin, teicoplanin, and the streptogramins: quinupristin and dalfopristin, p. 382-392. In G. E. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, Pa.
21. Fish, D. N., and A. T. Chow. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:101-119.
22. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A):73-82.
23. Gajjar, D. A., A. Bello, Z. Ge, L. Christopher, and D. M. Grasela. 2003. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. 47:2256-2263.
24. Garcia, I., A. Pascual, S. Ballesta, C. del Castillo, and E. J. Perea. 2003. Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 52:24-28.
25. Giesbrecht, P., T. Kersten, H. Maidhof, and J. Wecke. 1998. Staphylococcal cell wall: morphogenesis and fatal variations in the presence of penicillin. Microbiol. Mol. Biol. Rev. 62:1371-1414.
26. Gilbert, D. N. 2000. Aminoglycosides, p. 307-336. In G. E. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, Pa.
27. Glew, R. H., and R. C. Moellering, Jr. 1979. Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob. Agents Chemother. 15:87-92.
28. Gotoh, M., Y. Takamoto, K. Kurosaka, J. Masuda, M. Ida, A. Satoh, E. Takayama, K. Kojima-Aikawa, Y. Kobayashi, and I. Matsumoto. 2005. Annexins I and IV inhibit Staphylococcus aurcus attachment to human macrophages. Immunol. Lett. 98:297-302.
29. Grosset, J., L. Chauvelot-Moachon, and J. P. Giroud. 1988. Antituberculeux, p. 1553-1573. In J. P. Giroud, G. Mathé, and G. Meyniel (ed.), Pharmacologie clinique, bases de la thérapeutique. Expansion Scientifique Française, Paris, France.
30. Hebert, A., K. Sayasith, S. Senechal, P. Dubreuil, and J. Lagace. 2000. Demonstration of intracellular Staphylococcus aureus in bovine mastitis alveolar cells and macrophages isolated from naturally infected cow milk. FEMS Microbiol. Lett. 193:57-62.
31. Hess, D. J., M. J. Henry-Stanley, E. A. Erickson, and C. L. Wells. 2003. Intracellular survival of Staphylococcus aureus within cultured enterocytes. J. Surg. Res. 114:42-49.
32. Hoffken, G., H. Lode, C. Prinzing, K. Borner, and P. Koeppe. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother. 27:375-379.
33. Israel, D., J. G. Gillum, M. Turik, K. Harvey, J. Ford, H. Dalton, M. Towle, R. Echols, A. H. Heller, and R. Polk. 1993. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob. Agents Chemother. 37:2193-2199.
34. Jett, B. D., and M. S. Gilmore. 2002. Host-parasite interactions in Staphylococcus aureus keratitis. DNA Cell Biol. 21:397-404.
35. Kapral, F. A., and M. G. Shayegani. 1959. Intracellular survival of staphylococci. J. Exp. Med. 110:123-128.
36. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
37. Matsumoto, Y., A. Ikemoto, Y. Wakai, F. Ikeda, S. Tawara, and K. Matsumoto. 2001. Mechanism of therapeutic effectiveness of cefixime against typhoid fever. Antimicrob. Agents Chemother. 45:2450-2454.
38. Maurin, M., and D. Raoult. 1994. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J. Infect. Dis. 169:330-336.
39. Mempel, M., C. Schnopp, M. Hojka, H. Fesq, S. Weidinger, M. Schaller, H. C. Korting, J. Ring, and D. Abeck. 2002. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br. J. Dermatol. 146:943-951.
40. Mercier, R. C., and L. Hrebickova. 2005. Oritavancin: a new avenue for resistant gram-positive bacteria. Expert Rev. Anti. Infect. Ther. 3:325-332.
41. Michot, J. M., C. Seral, F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 49:2429-2437.
42. Motulsky, H. J. 2005. Analyzing data with GraphPad Prism. http://www .graphpad.com. GraphPad Software Inc., San Diego, Calif. (last updated, 1999; last accessed, 2 August 2005).
43. Myers, D. R., J. DeFehr, W. M. Bennet, G. A. Porter, and G. D. Olsen. 1978. Gentamicin binding to serum and plasma proteins. Clin. Pharmacol. Ther. 23:356-360.
44. Namour, F., D. H. Wessels, M. H. Pascual, D. Reynolds, E. Sultan, and B. Lenfant. 2001. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. 45:170-175.
45. Nielsen, S. L., and F. T. Black. 1998. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J. Antimicrob. Chemother. 42:221-226.
46. Ohkuma, S., and B. Poole. 1978. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. USA 75:3327-3331.
47. Ouadrhiri, Y., B. Scorneaux, Y. Sibille, and P. M. Tulkens. 1999. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob. Agents Chemother. 43:1242-1251.
48. Paillard, D., J. Grellet, V. Dubois, M. C. Saux, and C. Quentin. 2002. Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model. Antimicrob. Agents Chemother. 46:288-293.
49. Peck, O. M., H. Fan, G. E. Tempel, G. Teti, P. V. Halushka, and J. A. Cook. 2004. Staphylococcus aureus and lipopolysaceharide induce homologous tolerance but heterologous priming: role of interferon-gamma. Shock 21:254-260.
50. Philippon, A., G. Paul, F. Brunet, and J. P. Giroud. 1988. Pénicillines, p. 1295-1329. In 3. P. Giroud, G. Mathé, and G. Meyniel (ed.), Pharmacologic clinique, bases de la thérapeutique. Expansion Scientifique Française, Paris, France.
51. Proctor, R. A., J. M. Balwit, and O. Vesga. 1994. Variant subpopulations of Staphyloeoccus aureus as cause of persistent and recurrent infections. Infect. Agents Dis. 3:302-312.
52. Rogers, D. E., and R. Tompsett. 1952. The survival of staphylococci within human leukocytes. J. Exp. Med. 95:209-230.
53. Ross, E. M., and T. Kenakin. 2001. Pharmacodynamics: mechanism of drug action and the relationship between drug concentration and effect, p. 31-43. In J. Hardman and L. E. Limbird (ed.), Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill Medical Publishing Division, New York, N.Y.
54. Schwab, J. C., and G. L. Mandell. 1989. The importance of penetration of antimicrobial agents into cells. Infect. Dis. Clin. N. Am. 3:461-467.
55. Scorneaux, B., Y. Ouadrhiri, G. Anzalone, and P. M. Tulkens. 1996. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob. Agents Chemother. 40:1225-1230.
56. Seral, C., M. Barcia-Macay, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2005. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphyloeoccus aureus in J774 macrophages. J. Antimicrob. Chemother. 55:511-517.
57. Seral, C., F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292.
58. Stass, H., A. Dalhoff, D. Kubitza, and U. Schuhly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
59. Sullivan, J. T., M. Woodruff, J. Lettieri, V. Agarwal, G. J. Krol, P. T. Leese, S. Watson, and A. H. Heller. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob. Agents Chemother. 43:2793-2797.
60. Tano, E., O. Cars, and E. Lowdin. 2005. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. J. Antimicrob. Chemother. 56:240-242.
61. Tome, J. P., M. G. Neves, A. C. Tome, J. A. Cavaleiro, M. Soncin, M. Magaraggia, S. Ferro, and G. Jori. 2004. Synthesis and antibacterial activity of new poly-S-lysine-porphyrin conjugates. J. Med. Chem. 47:6649-6652.
62. Tulkens, P., and A. Trouet. 1978. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem. Pharmacol. 27:415-424.
63. Tyteca, D., P. Van Der Smissen, M. Mettlen, F. Van Bambeke, P. M. Tulkens, M. P. Mingeot-Leclercq, and P. J. Courtoy. 2002. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp. Cell Res. 281:86-100.
64. Van Bambeke, F., S. Carryn, C. Seral, H. Chanteux, D. Tyteca, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48:2853-2860.
65. Van Bambeke, F., Y. Van Laethem, P. Courvalin, and P. M. Tulkens. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936.
66. van den Broek, P. J. 1991. Activity of antibiotics against microorganisms ingested by mononuclear phagocytes. Eur. J. Clin. Microbiol. Infect. Dis. 10:114-118.
67. van den Broek, P. J., L. F. Buys, H. Mattie, and R. van Furth. 1986. Comparison of the effect of phenoxymethylpenicillin, cloxacillin, and flucloxacillin on Staphylococcus aureus phagocytosed by human monocytes. J. Antimicrob. Chemother. 17:767-774.
68. Waldvogel, F. A. 2000. Staphylococcus aureus, p. 2069-2092. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, Pa.
69. Weinrick, B., P. M. Dunman, F. McAleese, E. Murphy, S. J. Projan, Y. Fang, and R. P. Novick. 2004. Effect of mild acid on gene expression in Staphylococcus aureus. J. Bacteriol. 186:8407-8423.
70. Yancey, R. J., M. S. Sanchez, and C. W. Ford. 1991. Activity of antibiotics against Staphylococcus aureus within polymorphonuclear neutrophils. Eur. J. Clin. Microbiol. Infect. Dis. 10:107-113.
71. Zhanel, G. G., A. K. Wierzbowski, P. Hisanaga, and D. J. Hoban. 2004. The use of ketolides in treatment of upper respiratory tract infections. Curr. Infect. Dis. Rep. 6:191-199.